Last reviewed · How we verify
Individualized dose of rituximab
The individualized dose of rituximab, developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, is currently marketed but lacks detailed revenue figures. A key strength is the protection of its composition patent, which expires in 2028, providing a period of exclusivity. The primary risk lies in the lack of specified competitors and trial results, which may impact market positioning and adoption.
At a glance
| Generic name | Individualized dose of rituximab |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome (NA)
- Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus (PHASE4)
- Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: